anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The purpose of this study was to investigate the peripheral and central auditory pathways in adult individuals after COVID-19 infection.
METHOD: A total of 44 individuals aged between 19 and 58 years, of both genders, post-COVID-19 infection, confirmed by serological tests, with no previous hearing complaints and no risk factors for hearing loss, were assessed. All the participants underwent the following procedures: pure tone audiometry, logoaudiometry, immitanciometry, and Brainstem Auditory Evoked Potentials (BAEP), in addition to answering a questionnaire about auditory symptoms.
RESULTS: Thirteen individuals (29.5 %) had some hearing threshold impairment, mainly sensorineural hearing loss. In the BAEP, 18 individuals (40.9 %) presented longer latencies, mainly in waves III and V. According to the questionnaire answers, 3 individuals (9.1 %) reported worsened hearing and 7 (15.9 %) tinnitus that emerged after the infection. As for the use of ototoxic drugs during treatment, 7 individuals (15.9 %) reported their use, of which 5 showed abnormalities in peripheral and/or central auditory assessments.
CONCLUSION: Considering the self-reported hearing complaints after COVID-19 infection and the high rate of abnormalities found in both peripheral and central audiological assessments, it is suggested that the new COVID-19 may compromise the auditory system. Due to the many variables involved in this study, the results should be considered with caution. However, it is essential that audiological evaluations are carried out on post-COVID-19 patients in order to assess the effects of the infection in the short, medium, and long term. Future longitudinal investigations are important for a better understanding of the auditory consequences of COVID-19.
BACKGROUND: Venous access in patients with obesity presents significant challenges. The success of central venous catheterisation largely depends on the cross-sectional area (CSA) of the internal jugular vein (IJV). While techniques like the Trendelenburg position have been traditionally used to increase IJV CSA, recent studies suggest its ineffectiveness in patients with obesity. Conversely, the potential of the effect of passive leg raising (PLR) has not been thoroughly investigated in this group of patients.
METHODS: This protocol outlines a planned randomised controlled trial to evaluate the effect of PLR on the CSA of the IJV in patients with obesity slated for central venous catheterisation. The protocol involves dividing 40 participants into two groups: one undergoing PLR and another serving as a control group without positional change. The protocol specifies measuring the CSA of the IJV via ultrasound as the primary outcome. Secondary outcomes will include the success rates of right IJV cannulation. The proposed statistical approach includes the use of t-tests to compare the changes in CSA between the two groups, with a significance threshold set at p<0.05.
ETHICS APPROVAL: This study has been approved by the Institutional Review Board of Shanghai Tongren Hospital. All the participants will provide informed consent prior to enrolment in the study. Regarding the dissemination of research findings, we plan to share the results through academic conferences and peer-reviewed publications. Additionally, we will communicate our findings to the public and professional communities, including patient advocacy groups.
TRIAL REGISTRATION NUMBER: ChiCTR: ChiCTR2400080513.
Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
Patients with locally advanced unresectable, recurrent and/or metastatic HCC who have progressed on 1 prior systemic treatment, which must have included anti-programmed cell death 1 (PD-1)/anti-PD-L1 therapy. Patients will receive atezolizumab plus bevacizumab therapy combined with RP2.
Ischemia-reperfusion injury (IRI) often stems from an imbalance between mitochondrial dynamics and autophagy. Melatonin mitigates IRI by regulating mitochondrial dynamics. However, the precise molecular mechanism underlying the role of melatonin in reducing IRI through modulating mitochondrial dynamics remains elusive. The objective of this study was to investigate whether pretreatment with melatonin before IRI confers protective effects by modulating mitochondrial dynamics and mitophagy. Melatonin pretreatment was administered to HK-2 cells and live rats before subjecting them to hypoxia-reoxygenation or IRI, respectively. Cells and rat kidney models were evaluated for markers of oxidative stress, autophagy, mitochondrial dynamics, and the expression of adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) and phospho-AMPKα (P-AMPK). After renal IRI, increased mitochondrial fission and autophagy were observed, accompanied by exacerbated cellular oxidative stress injury and aggravated mitochondrial dysfunction. Nevertheless, melatonin pretreatment inhibited mitochondrial fission, promoted mitochondrial fusion, and attenuated autophagy levels. This intervention was correlated with a notable reduction in oxidative stress injury and remarkable restoration of mitochondrial functionality. Ischemia-reperfusion injury led to a decline in P-AMPK levels, whereas melatonin pretreatment increased the level of P-AMPK levels. Silencing AMPK with small interfering RNA exacerbated mitochondrial damage, and in this context, melatonin pretreatment did not alleviate mitochondrial fission or autophagy levels but resulted in sustained oxidative stress damage. Collectively, these findings indicate that melatonin pretreatment shields the kidneys from IRI by mitigating excessive mitochondrial fission, moderating autophagy levels, and preserving appropriate mitochondrial fission, all in an AMPK-dependent manner.
A vaccine containing a Sendai virus vector which encodes the viral protein of immunodeficiency virus. Efficient protective immunity can be successfully induced by nasally administering a Sendai virus encoding the viral protein of immunodeficiency virus to macaque. By nasally inoculating the vaccine, the expression of an antigen gene mediated by the Sendai virus vector is detected in the nasal mucosa and local lymph nodes and an antigen-specific cell- mediated immune response is induced at a significant level. No pathological sign caused by the vaccination is observed. When the effect is examined by exposing the vaccinated animal to Simian immunodeficiency virus, a significant decrease in the plasma virus level is observed compared with a control animal. This vaccine is likely useful as an AIDS vaccine.
The present invention provides a method of treating or preventing complement-mediated immune disease in a subject, comprising administering to the subject an inhibitor of synthesis or activity of Factor B, whereby the inhibition of synthesis or activity of Factor B treats or prevents the immune disease. Also provided are an antibody to Factor B, an anti-sense oligonucleotide which blocks the mRNA which encodes Factor B and a peptide which competitively binds C3, the receptor for Factor B. The present invention further provides a vector comprising the nucleic acid of this invention and a cell comprising the vector. Also provided is a method of administering to a subject in a pharmaceutically acceptable carrier an antibody, oligonucleotide, peptide and vector of the invention. The present invention further provides a method of determining the predisposition of a subject to complement-mediated immune disease and a method of determining efficacy of treatment in and prognosis of a subject with complement-mediated immune disease. Further, the present invention also provides a mutant transgenic mouse.
The COVID-19, caused by SARS-CoV-2, first affects the respiratory tract but evidence is emerging that the virus, reaching the central nervous system (CNS), can lead to severe neurological disorders. In particular, CoV infection could cause an acceleration of the neurodegenerative process. On the other hand, patients diagnosed with Alzheimer's disease (AD) develop more serious forms of COVID-19 with worse relapses. Therefore, understanding the connection between the two pathologies, AD and infection by coronavirus, could help in the development of new therapeutic approaches to counter them. We used the SH-SY5Y cell line differentiated into neurons, as widely used in studies of AD if supplemented with exogenous fibrillary β-amyloid (Aβ). As a glial counterpart, human microglia (HMC3) and astrocytic (D54MG) cell lines were used to create co-cultures with neurons via transwell systems. In these experimental models, we generated infection with the Human Coronavirus OC43 (HCoV-OC43), a low-risk model of SARS-CoV-2. Our results suggest that the infection by HCoV-OC43 leads to a neurotoxic effect not depending on an already present event of Aβ deposition. Indeed, unlike microglia, neurons and even more astrocytes are susceptible to CoV infection and, although the infection does not show a cytotoxic effect in the neurons in the first few days, significant alterations at a biochemical and morphological level have been observed, suggesting that the neurons are reacting to a stressful condition, including the prodromal and neurodegenerative features of AD. Interestingly, the interaction of infected astrocytes with the neurons resulted in the manifestation of signs of neurodegeneration, such as amyloid-beta deposition. By using exogenous fibrillary Aβ, as an AD in vitro model, our data suggest that there is an aggravating effect both on the infection itself and on the neurological disease progression. In conclusion, the results of this study suggest a causal interplay between HCoV-OC43 and neurological diseases and demonstrate that the co-presence of different CNS cell populations is the necessary condition to study the pathogenic effects in vitro as a whole.
PURPOSE: To provide a complement inhibitor useful as a medicine for treating and preventing of an inflammatory dermatosis, intestinal disease and purpura. CONSTITUTION: This medicine is the complement inhibitor and particularly its C1 inactivator and I factor or H factor has an action to suppress Arthus reaction. The soln. contg. such C1 inactivator and I factor or H factor is useful for prevention and treatment of the inflammatory dermatosis; for example, pustular skin disease, dermatitis group, psoriasis, intestinal disease, particularly, Chrohn's disease, tumorous colon inflammation and inflammatory purpura. The soln. allows intravenous, intramuscular or subcutaneous administration and the dosage thereof is the C1 inactivator: 1 to 500 IU/kg/day, the I factor: 0.05 to 100 mg/BW/day, the H factor: 0.005 to 100 mg/kg/BW/day. The separate administration of these inhibitors or the administration in combination thereof is possible.
This study examined the association between media and Instagram interaction patterns with weight bias among undergraduate nutrition students in the Brazilian Nutritionists' Health Study. We also explored the potential mediating role of students' own body image perception in these relationships. A total of 406 students (78% women) participated in this cross-sectional analysis. Sociodemographic data, media influence, Instagram interaction patterns, body image perception, and weight bias were assessed using semi-structured questionnaires. Findings indicated that exposure to fitness content on Instagram (β = 0.17, p < 0.001) and the pursuit of an ideal athletic body (β = 0.12, p = 0.034) were associated with increased weight bias. In contrast, engagement with body diversity content (β = -0.23, p < 0.001) and perceived pressure from media to conform to appearance ideals (β = -0.24, p < 0.001) had a mitigating effect on weight bias. Notably, body image perception did not mediate these relationships (p > 0.05). In conclusion, this study revealed a link between media exposure and weight bias among undergraduate nutrition students, independent of their body image perception. Developing social media literacy programs that encourage students to critically evaluate media content is imperative to reduce weight bias. Additionally, a deeper examination of the media content that contributes to weight bias and the potential need for targeted regulatory measures is warranted.
AIM: To present a comprehensive analysis of the clinical features and magnetic resonance imaging (MRI) findings of intracranial tuberculomas in Indonesia.
MATERIALS AND METHODS: This was a retrospective analysis of brain MRI from 58 patients (29 women), mean age ± SD = 39 ± 2 years, diagnosed with intracranial tuberculomas. Clinical data, including symptoms, cerebrospinal fluid examination results, and MRI were also analysed. The diagnosis of intracranial tuberculoma was confirmed based on observed MRI changes following anti-tuberculosis therapy.
RESULTS: A total of 603 tuberculomas were fully detected via MRI in all patients. Among these lesions, 507 (84%) were located in the cerebrum, 61 (10%) in the cerebellum, 19 (3%) in the basal ganglia, 12 (2%) in the brain stem, and four (1%) in the thalamus. The MRI signals were classified into two groups: tuberculomas with caseating granulomas and tuberculomas with non-caseating granulomas. Among the patients, 29 had concomitant meningitis, seven had hydrocephalus, and four had cerebral infarction. Evidence of pulmonary tuberculosis was found in 16 patients, with one patient having coexisting thoracic vertebral tuberculosis.
CONCLUSION: The present study confirmed the significance of MRI as a valuable tool in the diagnosis of intracranial tuberculomas and the detection of associated abnormalities. The combination of MRI findings with clinical features can enhance the overall diagnostic accuracy for intracranial tuberculomas.
Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
The subjects in active-tDCS priming with MCE group will receive the tDCS using 5X7 cm electrodes in which anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes. After that, the subjects will receive 20-minute MCE.
Conduct a comparative evaluation of the effectiveness and safety of Luspatercept combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly diagnosed non-transfusion-dependent non-severe aplastic anemia (NSAA). Patients were randomized in a 1:1 ratio and assigned to one of two groups: Group A, Luspatercept combined with cyclosporine: received Luspatercept (1.0 mg/kg, subcutaneous injection every 3 weeks), cyclosporine (3-5mg/kg/day), adjusted based on hematological parameters, for at least 6 months to assess efficacy. Effective patients continued to receive cyclosporine treatment for at least 1.5 years, with a gradual reduction in dosage; Group B, cyclosporine: received 3-5mg/kg/day, adjusted based on hematological parameters, for at least 6 months to assess efficacy, with effective patients continuing to receive cyclosporine treatment for at least 1.5 years, with a gradual reduction in dosage. Hgb below 60g/L was allowed, or in emergency conditions, blood transfusion was allowed. Platelets below 20×10\^9/L or with obvious bleeding tendency were allowed to receive platelet transfusion. If neutrophil count was below 1.0×10\^9/L, G-CSF was allowed until neutrophil count recovered to above 1.0×10\^9/L. Symptoms, treatment-related adverse events, signs, blood transfusion volume, and laboratory tests (including reticulocyte count) were recorded at least every 3 months for the first 3 months, and every 6 months thereafter until 6 months, and bone marrow aspiration, biopsy, and chromosome examination were performed at least every 6 months to observe efficacy and safety.
Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
The present invention is directed to a vaginal insert (134) for delivering an agent to a urogenital tract in a patient. The patient has a vagina, and the vagina has a vagina wall. The vaginal insert (134) comprises a base member (136) sized to fit within the vagina, the base member defines a chamber (142) and a port (144) in fluid communication with the chamber. A membrane (148) is operatively connected to the base member. The membrane defines a reservoir (150) and a pore. The reservoir is in fluid communication with the port. The membrane is sized so that the vaginal wall will exert pressure against the membrane when fluid is in the reservoir, thereby forcing some of the fluid to flow through the pore and to tissue of the urogenital tract.
The invention discloses a method for preparing pure natural care components in cosmetics by natural degradation of fruits and a formula. Sold fruits are cleaned with tap water and are cut into small blocks with sizes of below 1 centimeter; after being weighed, the fruits are added into a fermentor, the volume of the fruits is kept at no less than 1/3 that of the fermentor, so that the fruits are naturally degraded; and the degradation liquid acidity is detected everyday. After the pH of the degradation liquid reaches 3-4, water accounting for 1/5 the weight of the fruits is added, fermentation continues to be performed until the pH of the degradation liquid is 3-4, and water is added. The above-mentioned process is repeated until the fermentor is filled with water. The fermentor is sealed at room temperature of 20-39 DEG C to continue to perform temperature control fermentation for 90 days or above. The fermentor is unpacked after a fermentation stage is up, and degradation stock solution is filtered and extracted in an aseptic chamber. After the aseptic examination of fruit degradation stock solution passes, the fruit degradation stock solution is filled to serve as cosmetic components, or the fruit degradation stock solution is diluted by 5-15 times with tap water having undergone heating and sterilization treatment to be used directly. The invention discloses the method for preparing the pure natural care components in the cosmetics by natural degradation of the fruits. Sunscreen components of the natural cosmetics prepared through the method are free of artificial pigments and chemical functional components and have no adverse excitation to the skin.
PROBLEM TO BE SOLVED: To obtain a synthetic catalyst oligonucleotide structure which can cleave the target sequence of a nucleic acid and is useful as a diagnostic reagent or the like by forming a specific chemical structure. SOLUTION: This synthetic catalyst oligonucleotide structure contain a nucleotide expressed by the formula [B is a nucloside base such as adenin-9-yl(A) or cytosin-1-yl(C); V is O or CH2; X and W are each O, S, NH2, a 1 to 10C, preferably 1 to 4C alkyl or alkoxy; R is H, a 1 to 10C alkyl, alkenyl, alkynyl, or the like]. Therein, R in the formula is the group except H in at least one nucleotide, and there is a nucleotide in which R in H in the catalytic active center. The catalytic active center of the oligonucleotide structure exhibits a hammer head or hair pin structure. The oligonucleotide structure contains a region for sharing a hybridization with the target sequence of nucleic acid. The synthetic catalyst nucleotide structure is preferably used for cleaving the target sequence of a nucleic acid such as ribonucleic acid.
OBJECTIVE: To identify risk factors associated with in-hospital seizures and new-onset epilepsy in patients with aneurysmal subarachnoid hemorrhage (SAH) who underwent coiling embolization or clipping surgery.
METHODS: This retrospective descriptive study included 195 patients diagnosed with aneurysmal SAH and treated with coiling embolization or clipping surgery between January 2018 and June 2022.
RESULTS: Among the 195 patients meeting inclusion criteria, 9 experienced an onset seizure at the time of SAH. In-hospital seizures were observed in 33 patients, of which 24 were electrographic seizures detected in 24 patients with suspected subclinical seizures. After 12 months of follow-up, 11 patients met criteria for diagnosis of epilepsy. The incidence of epilepsy after discharge at 12 months was 2.41% in the coiling group and 8.03% in the clipping group. The risk of in-hospital seizures was significantly higher in the clipping group (P = 0.007), although the difference was not statistically significant after 12 months of follow-up (P = 0.121).
CONCLUSIONS: Epilepsy following aneurysmal SAH was relatively common. Clipping surgery and brain edema emerged as independent predictive factors for in-hospital seizures, while onset seizures and in-hospital seizures were identified as independent predictors of epilepsy during follow-up. Patients presenting with these risk factors may benefit from long-term electroencephalogram monitoring and should be considered for prophylactic antiepileptic drugs. Additionally, lumbar drainage proved effective in improving both early and late epileptic outcomes in the group with Fisher grades 3 and 4.
A method for improved cardiac monitoring is disclosed. The method includes receiving image data from an image sensor configured for monitoring edema in a patient. Additional data is received from one or more additional sensors configured to monitor one or more factors related to cardiac activity of the patient. The received image data is fused with the received additional data from the one or more additional sensors to generate fused data set. A cardiac condition for the patient is determined based on the fused data set. A cardiac monitoring computing device and non-transitory medium are also disclosed.
This study arm will provided with access to all varieties of 4mg on! nicotine pouch products throughout the trial.